JelloX Debut Highlights Potential to Disrupt Cancer Pathology
Retrieved on:
Tuesday, November 8, 2022
Diagnosis, FDA, The Harvard Gazette, Biomarker, Attention, Budget, Digital, SAN, Cancer, Privacy, Medical device, National Tsing Hua University, Software, Biotechnology, Algorithm, Intel, Marie Cassidy, COVID-19, 3D, Approximation error, Neoplasm, Oncology, Pathology, Efficiency, AI, Multimedia, Technology, Medical imaging
SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- JelloX Biotech's debut at Intel Innovation in September drew the attention of healthcare experts and pharmaceutical brands alike for the Taiwan-based startup's potential to shape the future of cancer pathology using 3D imaging technology.
Key Points:
- SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- JelloX Biotech's debut at Intel Innovation in September drew the attention of healthcare experts and pharmaceutical brands alike for the Taiwan-based startup's potential to shape the future of cancer pathology using 3D imaging technology.
- "JelloX Biotech envisions a world where AI-driven 3D pathology empowers healthcare providers by making cancer diagnosis more precise, faster, and less costly," notes JelloX Biotech CEO Dr. Yen-Yin Lin.
- MetaLiteelevates efficiency and effectiveness by addressing the extensive labor costs, painstaking processes, and myriad technical expenses associated with cancer pathology.
- Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup founded by researchers from National Tsing Hua University that focuses on advancing cancer pathology through digital and 3D imaging and AI technology.